1. Home
  2. TGTX vs CNM Comparison

TGTX vs CNM Comparison

Compare TGTX & CNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$55.16

Market Cap

8.5B

Sector

Health Care

ML Signal

HOLD

Logo Core & Main Inc.

CNM

Core & Main Inc.

HOLD

Current Price

$42.91

Market Cap

7.9B

ML Signal

HOLD

Company Overview

Basic Information
Metric
TGTX
CNM
Founded
1993
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Durable Goods
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
8.5B
7.9B
IPO Year
2008
2021

Fundamental Metrics

Financial Performance
Metric
TGTX
CNM
Price
$55.16
$42.91
Analyst Decision
Strong Buy
Buy
Analyst Count
5
11
Target Price
$49.80
$61.55
AVG Volume (30 Days)
1.5M
2.7M
Earning Date
05-04-2026
06-09-2026
Dividend Yield
N/A
N/A
EPS Growth
1746.67
8.45
EPS
0.17
1.34
Revenue
$2,785,000.00
$7,647,000,000.00
Revenue This Year
$49.08
$4.89
Revenue Next Year
$26.69
$4.21
P/E Ratio
$341.82
$32.10
Revenue Growth
N/A
2.77
52 Week Low
$26.76
$40.03
52 Week High
$59.30
$59.66

Technical Indicators

Market Signals
Indicator
TGTX
CNM
Relative Strength Index (RSI) 61.78 N/A
Support Level $51.76 N/A
Resistance Level $58.12 N/A
Average True Range (ATR) 2.02 0.00
MACD 0.21 0.00
Stochastic Oscillator 84.03 0.00

Price Performance

Historical Comparison
TGTX
CNM

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

About CNM Core & Main Inc.

Core & Main is a leading specialty distributor with a focus on water, wastewater, storm drainage, and fire protection products. The company provides solutions to municipalities, private water companies, and professional contractors across municipal, nonresidential, and residential end markets. The company's specialty products and services are used in the maintenance, repair, replacement, and construction of water and fire protection infrastructure.

Share on Social Networks: